A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT2C Receptors in Rats: Implication of the Subthalamic Nucleus.

International Journal of Molecular Sciences
Mélanie LagièrePhilippe De Deurwaerdère

Abstract

Dopaminergic medication for Parkinson's disease is associated with troubling dystonia and dyskinesia and, in rodents, dopaminergic agonists likewise induce a variety of orofacial motor responses, certain of which are mimicked by serotonin2C (5-HT2C) receptor agonists. However, the neural substrates underlying these communalities and their interrelationship remain unclear. In Sprague-Dawley rats, the dopaminergic agonist, apomorphine (0.03-0.3 mg/kg) and the preferential D2/3 receptor agonist quinpirole (0.2-0.5 mg/kg), induced purposeless oral movements (chewing, jaw tremor, tongue darting). The 5-HT2C receptor antagonist 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) (1 mg/kg) reduced the oral responses elicited by specific doses of both agonists (0.1 mg/kg apomorphine; 0.5 mg/kg quinpirole). After having confirmed that the oral bouts induced by quinpirole 0.5 mg/kg were blocked by another 5-HT2C antagonist (6-chloro-5-methyl-1-[6-(2-methylpiridin-3-yloxy)pyridine-3-yl carbamoyl] indoline (SB 242084), 1 mg/kg), we mapped the changes in neuronal activity in numerous sub-territories of the basal ganglia using c-Fos expression. We found a marked increase of c-Fos expression in t...Continue Reading

References

Mar 1, 1992·Pharmacology, Biochemistry, and Behavior·L Gong, R M Kostrzewa
Mar 14, 1989·European Journal of Pharmacology·B R StewartC D Marsden
Apr 1, 1995·Pharmacology, Biochemistry, and Behavior·R BrusR M Kostrzewa
Aug 1, 1994·Experimental Neurology·T J ParryM F Chesselet
May 1, 1996·Neuroscience·K Eberle-WangM F Chesselet
Apr 1, 1997·Neuropharmacology·G A KennettT P Blackburn
Jan 13, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·H RosengartenA J Friedhoff
Mar 27, 2001·Pharmacology, Biochemistry, and Behavior·A MehtaM F Chesselet
Jun 18, 2002·Neuroscience Research·Atsushi NambuMasahiko Takada
Apr 2, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Philippe De DeurwaerdèreUmberto Spampinato
Mar 2, 2005·Journal of Neurophysiology·Zixiu XiangStephen T Kitai
Apr 19, 2005·The Journal of Pharmacology and Experimental Therapeutics·Gregory T CollinsJames H Woods
Aug 19, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Bertrand DegosNicolas Maurice
Mar 15, 2008·The International Journal of Neuropsychopharmacology·Shlomit Flaisher-GrinbergDaphna Joel
Jun 13, 2008·The European Journal of Neuroscience·Bertrand DegosNicolas Maurice
Sep 6, 2008·Progress in Brain Research·Neil M Richtand, Robert K McNamara
Dec 17, 2008·Current Opinion in Neurobiology·Atsushi Nambu
Jan 30, 2010·Parkinsonism & Related Disorders·Mahlon DeLong, Thomas Wichmann
Oct 16, 2010·The International Journal of Neuropsychopharmacology·Mark J MillanClotilde Mannoury la Cour

❮ Previous
Next ❯

Software Mentioned

Mercator
Scope
Sigmaplot
MATLAB
Spike
Neuroexplorer
Chart

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.